Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS

Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS

US Patent 9523687 · Granted Dec 20, 2016

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Diagnostic and therapeutic methods for cancer2024
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both2024
Anti-CD8 antibodies and uses thereof2023
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both2022
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both2021
Treatments to eliminate HIV reservoirs and reduce viral load2020
Treatments to eliminate HIV reservoirs and reduce viral load2019
Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive2019
Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive2019
Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive2019
Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive2019
Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive2019